Cisplatin-Induced Anorexia and Ghrelin

Vitamins and Hormones

Volumn 92, Issue , 2013, Pages 301-317

  Hattori, Tomohisa ^a   Yakabi, Koji ^b   Takeda, Hiroshi ^c,d  

^a TSUMURA AND CO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Cisplatin; Ghrelin; Rikkunshito

Indexed keywords

EID: 84876715757     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-410473-0.00012-X     Document Type: Chapter

References (36)

1. Akamizu T., Iwakura H., Ariyasu H., Kangawa K. Ghrelin and functional dyspepsia. The International Journal of Peptide 2010, 2010. Pill 548457.
2. Akamizu T., Kangawa K. Therapeutic applications of ghrelin to cachexia utilizing its appetite-stimulating effect. Peptide 2011, 32(11):2295-2300.
3. Chaney S.G., Campbell S.I., Bassertt E., Wu Y. Recognition and processing of cisplatin-and oxaliplatin-DNA adducts. Critical Reviews in Oncology/Hematology 2005, 53(1):3-11.
4. Choi D.S., Maroteaux L. Immunohistochemical localization of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Letters 1996, 5(391):45-51.
5. Cox D.A., Cohen M.L. 5-HT2B receptor signaling in the rat stomach fundus: Dependence on calcium influx, calcium release and protein kinase C. Behavioural Brain Research 1996, 73(1-2):289-292.
6. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002, 123(4):1120-1128.
7. Date Y., Shimbara T., Koda S., Toshinai K., Ida T., Murakami N., et al. Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metabolism 2006, 4(4):323-331.
8. De Vry J., Schreiber R. Effects of selected 5-HT1 and 2 receptor agonists on feeding behavior: Possible mechanisms of action. Neuroscience and Biobehavioral Reviews 2000, 24(3):341-353.
9. Fujitsuka N., Asakawa A., Hayashi M., Sameshima M., Amitani H., Kojima S., et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. Biological Psychiatry 2009, 65:748-759.
10. Fujitsuka N., Asakawa A., Uezono Y., Minami K., Yamaguchi T., Niijima A., et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Translational Psychiatry 2011, 2011:1:e23.
11. Garcia J.M., Cata J.P., Dougherty P.M., Smith R.G. Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology 2008, 149(2):455-460.
12. Halford J.C., Harrold J.A., Boyland E.J., Lawton C.L., Blundell J.E. Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67(1):27-55.
13. Hattori T. A new strategy using Rikkunshito (Liu-Jun-Zi-Tang), a Japanese traditional medicine, to treat gastrointestinal disease. Basic of evidences-based herbal medicine 2010, 149-160. Research Signpost, Kerala, India. H. Satoh (Ed.).
14. Hiura Y., Takiguchi S., Yamamoto K., Kurosawa Y., Yamasaki M., Nakajima K., et al. Fall in plasma ghrelin concentration after cisplatin-based chemotherapy in esophageal cancer patients. International Journal of Clinical Oncology 2011, 17:316-323. 10.1007/s10147-011-0289-0.
15. Hong Y.S., Lee H.R., Park S., Lee S.C., Hwang I.G., Park B.B., et al. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. British Journal of Cancer 2006, 95(12):1648-1652. (Epub 2006 November 28).
16. Kojima M., Hosoda H., Date Y., Nakazato M., Matsumoto H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
17. Liu Y., Hamaue N., Endo T., Hirafuji M., Minami M. 5-Hydroxytryptamine (5-HT) concentrations in the hippocampus, the hypothalamus and the medulla oblongata related to cisplatin-induced PICA of rats. Research Communication in Molecular Pathologyand Pharmacology 2003, 113-114:97-113.
18. Malik N.M., Moore G.B.T., Kaur R., Liu Y.L., Wood S.L., Morrow R.W., et al. Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia. Regulatory Peptides 2008, 148:33-38.
19. Matsumura T., Arai M., Yonemitsu Y., Maruoka D., Tanaka T., Suzuki T., et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. Journal of Gastroenterology 2010, 45:300-307.
20. Minami M., Endo T., Hamaue N., Sertonin M. Anticancer drug-induced emesis. Yakugaku Zasshi 2004, 124(8):491-507.
21. Nonogaki K. Ghrelin and feedback systems. Vitamins and Hormones 2008, 77:149-170.
22. Nonogaki K., Stack A.M., Dallman M.F., Tecott L.H. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT(2C) receptor gene. Nature Medicine 1998, 4:1152-1156.
23. Ohno T., Yanai M., Ando H., Toyomatsu Y., Ogawa A., Morita H., et al. Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans. Clinical and Experimental Gastroenterology 2011, 4:291-296.
24. Roila F., Fatigoni S. New antiemetic drugs. Annals of Oncology 2006, 17(Suppl. 2):ii96-ii100.
25. Rudd J.A., Ngan M.P., Wai M.K., King A.G., Witherington J., Andrews P.L., et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent. Neuroscience Letters 2006, 392:79-83.
26. Saegusa Y., Takeda H., Muto S., Nakagawa K., Ohnishi S., Sadakane C., et al. Decreased plasma ghrelin contributes to anorexia following novelty stress. American Journal of Physiology. Endocrinology and Metabolism 2011, 301:E685-E696.
27. Sawchenko P.E., Swanson L.W. Central noradrenergic pathways for the integration of hypothalamic neuroendocrine and autonomic responses. Science 1981, 214(4521):685-687.
28. Tack J., Janssen P. Emerging drugs for functional dyspepsia. Expert Opinion on Emerging Drugs 2011, 16(2):283-292. Med. 4 (10)1152-1156.
29. Takeda H., Sadakane C., Hattori T., Katsurada T., Ohkawara T., Nagai K., et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008, 134(7):2004-2013.
30. Tecott L.H. Serotonin and the orchestration of energy balance. Cell Metabolism 2007, 6(5):352-361.
31. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. The New England Journal of Medicine 2005, 352(25):2589-2597.
32. Xu Y., Jones J.E., Kohno D., Williams K.W., Lee C.E., Choi M.J., et al. 5-HT2cRS expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008, 26(609):582-589.
33. Yakabi K., Kurosawa S., Tamai M., Yuzurihara M., Nahata M., Ohno S., et al. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regulatory Peptides 2010, 161:97-105.
34. Yakabi K., Noguchi M., Ohno S., Ro S., Onouchi T., Ochiai M., et al. Urocortin 1 reduces food intake and ghrelin secretion via CRF2 receptors. American Journal of Physiology-Encocrinology and Metabolism 2011, 301:E72-E82.
35. Yakabi K., Sadakane C., Noguchi M., Ohno S., Ro S., Chinen K., et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology 2010, 151:3773-3782.
36. Zdraveski Z.Z., Mello J.A., Farinelli C.K., Essigmann J.M., Marinus M.G. MutS preferentially recognized cisplatin-Over oxaliplatin-modified DNA. Journal of Biological Chemistry 2002, 277(2):1255-1260.